Duo Liu | Epidemiology | Best Researcher Award

Published on by Health Scientists

Prof. Duo Liu | Epidemiology | Best Researcher Award 

Deputy Director, Department of Clinical Pharmacy | Harbin Medical University | China

Professor Duo Liu, Chief Pharmacist and Doctoral Supervisor at Harbin Medical University Cancer Hospital, is a distinguished pharmaceutical scientist whose research has significantly advanced the fields of pharmacogenomics, pharmacoepidemiology, and precision oncology. With a strong background in medical genetics and pharmacology, Professor Liu has developed a research portfolio that bridges molecular pharmacology with clinical translation, focusing on the genetic mechanisms underlying cancer susceptibility, therapeutic response, and drug resistance. His pioneering contributions include transcriptome-wide association studies identifying novel genetic determinants of pancreatic and prostate cancer risk, as well as investigations into the role of NADPH oxidase polymorphisms and oxidative stress in tumor biology and treatment outcomes. Professor Liu’s scholarly work, published in leading international journals such as Cancer Research, Carcinogenesis, and International Journal of Cancer, has garnered wide recognition for its methodological rigor and clinical relevance. He has successfully led multiple national and institutional research grants, including projects supported by the National Natural Science Foundation of China, and has been honored with several prestigious distinctions for excellence in pharmaceutical sciences and young investigator achievements. As an active member of numerous professional societies, including the Chinese Pharmacological Society and the Anti-Cancer Association of China, Professor Liu contributes to shaping the evolving landscape of cancer pharmacotherapy and drug epidemiology. His collaborations with global research institutions, notably the University of Hawaii Cancer Center, underscore his commitment to advancing international scientific exchange and translational medicine. Through his leadership in clinical pharmacy and mentorship of emerging scientists, Professor Liu continues to drive innovation in personalized cancer treatment and rational drug use, promoting evidence-based healthcare practices that enhance patient outcomes and public health impact worldwide.

Profile: ORCID 

Featured Publications

1. Chen, C., Dong, Q., Wang, H., Dong, S., Wang, S., Lin, W., Jia, C., Dong, M., Jin, Y., & Liu, D. (2025, January 8). The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients. Annals of Hematology.

2. Wang, S. F., Dong, S. Q., Dong, Q., Lin, W. X., Dong, M., & Liu, D. (2024). Natural product-induced oxidative stress-synergistic anti-tumor effects of chemotherapeutic agents. Traditional Medicine Research.

3. Dong, S., Chen, C., Di, C., Wang, S., Dong, Q., Lin, W., & Liu, D. (2024, December). The association between NADPH oxidase 2 (NOX2) and drug resistance in cancer. Current Cancer Drug Targets.

4. Liu, D., Bae, Y. E., Zhu, J., Zhang, Z., Sun, Y., Deng, Y., Wu, C., & Wu, L. (2023, December 15). Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk. Carcinogenesis.

5. Liu, D., Zhao, T., Zhu, J., Sharapov, S., Tiys, E., & Wu, L. (2023, December 4). Associations between genetically predicted plasma N-glycans and pancreatic cancer risk. All Life.

Tana Takacova | Clinical Medicine | Best Researcher Award

Published on by Health Scientists

Dr. Tana Takacova | Clinical Medicine | Best Researcher Award

Oncologist | Asklepios Klinik Altona | Germany

Tana Takacova is a physician-scientist specializing in hematology, oncology, and internal medicine with a distinguished academic and clinical trajectory across leading European research and tertiary care institutions. Her expertise spans immuno-oncology, molecular oncology, hematologic malignancies, and translational cancer research, supported by advanced training in oncology from a major German university and extensive postgraduate exposure to molecular biosciences in the United States. She has held clinical roles in prominent university-affiliated hospitals, progressing through multidisciplinary departments including hematology, oncology, palliative medicine, internal medicine, rheumatology, nephrology, gastroenterology, and cardiology, complemented by ongoing training as a prehospital emergency physician. Dr. Takacova has contributed to multiple international research collaborations across Germany, Denmark, Italy, and Slovakia, advancing knowledge in cancer genetics, circulating tumor DNA, oncolytic virus-checkpoint inhibitor synergies, renal cell carcinoma biomarkers, and therapy response prediction. Her peer-reviewed scholarship includes original research articles, systematic reviews, and case-based contributions in oncology and immunology, with additional manuscripts in review and development, reflecting a sustained commitment to evidence-based innovation and emerging therapeutic paradigms in precision oncology. She has presented at international oncology and pharmacology congresses and participates in global research networks and professional societies, reinforcing a truly international academic presence. Her work integrates advanced laboratory skills, clinical trial supervision, systematic review methodology, and bioinformatics-supported analysis, underscoring strong translational orientation. She has been recognized by competitive research fellowships and academic awards and contributes to open-access medical knowledge through educational initiatives such as a freely accessible hematology atlas. Fluent in multiple languages and trained across diverse health systems, she brings a global perspective, resilience in high-pressure environments, and a collaborative approach to clinical care and research leadership, driven by a commitment to advancing cancer diagnostics, therapeutic precision, and equitable patient outcomes worldwide. She has 34 citations from 4 documents with an h-index of 2.

Profile: Scopus

Featured Publications

1. Tana Takacova (2025). Paraneoplastic papillitis as a precursor to colon carcinoma: A case of unexpected vision loss leading to early cancer detection. Oncology Research and Treatment.

Serhat Gürbüz | Clinical Medicine | Best Researcher Award

Published on by Health Scientists

Dr. Serhat Gürbüz | Clinical Medicine | Best Researcher Award 

Doctor of Medicine | University of Health Sciences | Turkey

Dr. Serhat Gürbüz, MD, MSc, is a distinguished Consultant in Orthopedics and Traumatology at the Metin Sabancı Baltalimanı Bone Diseases Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. His professional expertise centers on knee, shoulder, and sports surgery, integrating advanced arthroscopic techniques and evidence-based rehabilitation strategies to restore function and improve patient outcomes. Dr. Gürbüz has contributed substantially to the field through scholarly publications in reputable peer-reviewed and indexed journals, clinical presentations, and collaborative research projects focused on musculoskeletal disorders and joint preservation. His work demonstrates a commitment to combining clinical excellence with translational research, contributing to the evolution of orthopedic surgical standards and innovations in minimally invasive procedures. He has maintained active collaborations with national and international orthopedic research groups and serves as a peer reviewer and academic contributor within the global orthopedic community. Dr. Gürbüz’s clinical practice reflects a deep dedication to advancing patient-centered care, surgical innovation, and academic mentorship, fostering the development of future orthopedic specialists. His academic engagement and research productivity underscore his contribution to scientific knowledge dissemination and the enhancement of evidence-based orthopedic medicine. Through his multidisciplinary collaborations and continuous pursuit of clinical innovation, Dr. Gürbüz has strengthened the bridge between medical research and practical application, ultimately promoting better musculoskeletal health and improving the quality of life for patients across diverse populations. He has 6 citations from 9 documents with an h-index of 2.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Çelikoyar, M. M., Topsakal, O., & Gürbüz, S. (2019). Mobile technology for recording surgical procedures. Journal of Visual Communication in Medicine.

2. Imren, Y., Karslioglu, B., Dedeoglu, S. S., Cabuk, H., Atar, S., Gürbüz, S., … (2021). The effect of gluteus maximus tenotomy in primary total hip arthroplasty with posterior approach: Kinematic analysis of hip extensor strength. Journal of Orthopaedic Surgery.

3. Yüce, A., Yerli, M., Erkurt, N., Gürbüz, S., Çakar, M., & Adaş, M. (2022). Neutrophil-lymphocyte and C-reactive protein–albumin ratios as predictors of re-surgery in adult native knee septic arthritis. Journal of Clinical and Investigative Surgery.

4. Gürbüz, S., Bahar, H., Yavuz, U., Keskin, A., Karslioglu, B., & Solak, Y. (2025). Comparative efficacy of ChatGPT and DeepSeek in addressing patient queries on gonarthrosis and total knee arthroplasty. Arthroplasty Today.

5. Gürbüz, S., Ocak, O., Kir, M. C., Karslioglu, B., & Aki, S. (2025). Hyperchloremia at hospital admission for hip fractures is related with an increase in morbidity and mortality rates. Turkish Journal of Trauma and Emergency Surgery.

Dr. Serhat Gürbüz’s work advances global orthopedic science through innovative surgical techniques, evidence-based clinical research, and multidisciplinary collaborations that enhance musculoskeletal health. His commitment to patient-centered innovation and translational research contributes significantly to improving mobility, recovery, and quality of life in society worldwide.

Jian Feng | Clinical Medicine | Best Researcher Award

Published on by Health Scientists

Dr. Jian Feng | Clinical Medicine | Best Researcher Award

Doctor | The General Hospital of Western Theater Command | China

Dr. Jian Feng is an Attending Physician at the Intensive Care Unit of The General Hospital of Western Theater Command in Chengdu, Sichuan Province, China. He earned his medical degree and completed advanced training in critical care medicine, with a focus on sepsis, multiple organ failure, acute respiratory distress syndrome, and altitude sickness. Dr. Feng has led and participated in multiple provincial- and national-level research projects, including studies on ICU-acquired weakness, the role of curcumin in skeletal muscle preservation at high altitudes, and innovative interventions in critical care. He has published extensively, with over 11 SCI-indexed papers and numerous Chinese core journal articles as first or corresponding author, including high-impact works in Asian Journal of Surgery, Journal of Inflammation Research, and Frontiers in Cellular and Infection Microbiology. His contributions extend to medical innovation, holding multiple invention and utility model patents, and co-authoring the monograph Clinical Nutritional Therapy for Neurocritical Care. Dr. Feng has received recognition for his research and clinical excellence, including awards for innovation and translational medicine. Beyond his research, he serves as a reviewer for prestigious journals such as Heliyon and Medical Science Monitor, demonstrating his commitment to advancing scientific rigor and critical peer review in the field of critical care medicine. His work combines clinical expertise with innovative research, reflecting a dedication to improving patient outcomes and contributing to the scientific community at both national and international levels. He has 51 citations from 20 documents with an h-index of 4.

Profiles: Scopus | ORCID

Featured Publications

1. Wang, M., Huang, B., Chen, J., Rui, Z., Li, J., Fang, S., Fan, L., Feng, J., & Li, F. (2025). Artificial intelligence and machine learning in the research and application status of ICU-acquired weakness.

2. Liu, J., Xu, Z., Luo, S., Bai, Y., Feng, J., & Li, F. (2024). Risk factors for ICU-acquired weakness in sepsis patients: A retrospective study of 264 patients.

3. Tan, J., Huang, B., Luo, S., Li, R., Hou, J., Zhang, R., Wang, L., Liu, Y., Li, F., & Feng, J. (2024). A rare case of severe pneumonia combined with septic shock caused by Nocardia amamiensis.

4. Luo, H., Feng, J., Xue, G., Zhang, Y., Li, Y., Huang, X., Chen, X., You, S., Dong, H., & Li, L. (2023). Comparative efficacy and acceptability of 12 phosphorus-lowering drugs in adults with hyperphosphatemia and chronic kidney disease: A systematic review and network meta-analysis.

5. Luo, S., Wang, L., Xu, Z., Liu, J., Zhang, W., Feng, J., & Li, F. (2023). Isolation, identification and biological characteristics of phage vB-KpnP1 for carbapenem-resistant Klebsiella pneumoniae.